"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
February 19th, 2019
13.4K views
The goal of this protocol is to provide a step-by-step guide to perform 3-D "liver-on-a-chip" infection experiments with the hepatitis B virus.
Overview
This protocol provides a detailed guide for conducting 3-D "liver-on-a-chip" infection experiments using the hepatitis B virus. It aims to enhance understanding of hepatotropic infections and liver diseases.
Key Study Components
Area of Science
- Neuroscience
- Infectious Diseases
- Cell Biology
Background
- The technique recapitulates a hepatic microenvironment.
- It allows for extended maintenance of liver tissue.
- This model is naturally susceptible to hepatitis B infection.
- Drug testing can be performed in a physiological context.
Purpose of Study
- To investigate the role of liver resident cell populations in viral pathogenesis.
- To study longitudinal infection kinetics and mechanisms of viral replication.
- To evaluate immune invasion in a physiological model.
Methods Used
- Assembly of microfluidic plates for liver cell culture.
- Seeding primary human hepatocytes in a controlled environment.
- Maintaining flow rates to support cell viability.
- Long-term culture of liver-derived cells for infection studies.
Main Results
- Successful maintenance of liver tissue for extended periods.
- Demonstrated susceptibility of the model to hepatitis B infection.
- Facilitated drug testing studies in a physiological platform.
- Provided insights into hepatotropic infections and liver diseases.
Conclusions
- This method addresses fundamental constraints in hepatitis B research.
- It offers a platform for evaluating treatment strategies.
- Visual demonstrations are critical for successful implementation.
Frequently Asked Questions
What is the main advantage of the liver-on-a-chip model?
The model recapitulates a hepatic microenvironment that is naturally susceptible to hepatitis B infection.
How long can liver tissue be maintained in this model?
The liver tissue can be maintained for extended periods, allowing for longitudinal studies.
What are the implications of this technique?
It extends toward therapy or diagnosis of HBV infection and allows for drug testing studies.
What challenges might new users face?
New users may struggle with the detailed maintenance of liver tissue and specialized equipment.
Why is visual demonstration important?
Visual demonstrations help in understanding the assembly and operation of the culture system.
Can this method be applied to other diseases?
Yes, it can also be applied to studies of other hepatotropic infections and liver diseases.
Executive Industry Relevance
This liver-on-a-chip model addresses a critical bottleneck in hepatitis B virus (HBV) research by enabling physiological infection at low viral titers, overcoming the need for artificial enhancers like DMSO and PEG. It supports longitudinal studies of viral replication, immune interactions, and drug response in a differentiated hepatocyte microenvironment maintained for over 40 days. The system enhances predictive confidence in preclinical evaluation of curative therapies targeting covalently closed circular (ccc)DNA, directly impacting antiviral pipeline de-risking.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of host-pathogen interactions using primary human hepatocytes and Kupffer cells under physiological flow conditions.
- Operational Value: Supports mechanistic de-risking by modeling viral persistence and immune evasion in a tissue-relevant context.
Screening & Assay Development
- Scientific Value: Permits HBV infection detection with as few as 0.5 genome equivalents per cell, increasing assay sensitivity without chemical potentiators.
- Operational Value: Provides a reproducible, microfluidic platform for longitudinal antiviral screening with stable albumin and cytokine readouts.
Translational & Preclinical Research
- Scientific Value: Facilitates evaluation of curative strategies by monitoring cccDNA reduction and viral antigen clearance over extended culture periods.
- Operational Value: Enables assessment of drug combinations and sequential regimens under physiologically relevant infection kinetics.
Pipeline & Workflow Integration
The method integrates into antiviral discovery workflows by providing a physiologically relevant platform for target validation, lead optimization, and preclinical efficacy testing of HBV-directed therapeutics.
- Discovery Biology: Supports hypothesis testing on liver-resident cell contributions to viral pathogenesis and replication dynamics.
- Screening: Delivers quantitative, endpoint-resolved outputs such as HBV DNA, albumin secretion, and cytokine profiles for compound evaluation.
- Analytics: Enables longitudinal tracking of infection markers and host responses to inform dose-response and time-dependent drug effects.
- Translational Research: Connects early antiviral activity to preclinical continuity through stable, long-term culture of infected hepatocyte-Kupffer cell co-cultures.
- Enterprise Reuse: Establishes a reusable microfluidic infrastructure for studying hepatotropic viruses and liver-directed therapies beyond HBV.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in HBV life cycle studies by maintaining differentiated hepatocyte function and nonparenchymal cell interactions.
- Operational Value: Standardizes infection modeling through controlled flow rates, media exchange, and defined cellular composition.
- Strategic Value: Improves go/no-go decisions by enabling preclinical assessment of curative potential under physiological infection conditions.
- Portfolio Impact: Supports risk-adjusted prioritization of antiviral candidates based on longitudinal efficacy and toxicity profiles in a human-relevant system.
Implementation Considerations
- Requires expertise in microfluidic plate assembly, sterile technique, and primary hepatocyte handling.
- Depends on specialized instrumentation including precision torque tools, vacuum pumps, and humidified incubators with flow control.
- Necessitates cross-team standardization of media priming, flow direction protocols, and scheduled medium exchange every 48 hours.
- Involves adaptation considerations when extending to other liver-resident cell types or disease models beyond HBV.
- Limited by the technical complexity of long-term culture maintenance, which demands consistent monitoring of albumin secretion and cytokine viability markers.
Biopharma FAQs
Why does low-titer HBV infection matter for target validation?
The model supports infection with as little as 0.5 HBV genome equivalents per cell without DMSO or PEG, reflecting physiological relevance and enabling evaluation of antiviral mechanisms at clinically relevant viral loads.
How does isolating Kupffer cells as an independent variable improve discovery pipeline outcomes?
Co-culturing primary hepatocytes with Kupffer cells allows assessment of immune cell contributions to viral pathogenesis and cytokine-mediated modulation of infection, supporting mechanistic de-risking in target validation.
What quantitative dependent variable measurements enable preclinical assessment of curative therapies?
Stable secretion of human albumin and cytokines like IL-6 and TNF-alpha serve as functional readouts for hepatocyte viability and Kupffer cell activity, enabling longitudinal monitoring of infection and treatment effects over 40+ days.
Why do replication requirements matter for cross-functional collaboration in antiviral development?
The wash-and-replace medium protocol every 48 hours ensures consistent culture conditions, allowing reproducible infection kinetics and drug response data across teams and sites.
What statistical analysis capabilities are required before implementing this model in drug screening?
The system generates time-resolved, quantitative outputs such as HBV DNA levels and secretory markers, requiring longitudinal data analysis to compare treatment effects and assess significance across experimental groups.
